The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines after a safety concern was found to be unrelated ...
Novavax is already poised to benefit from a separate combined Covid-flu vaccine ... combined shot. Meanwhile, Moderna said last week that it plans to file for FDA approval of its own combo vaccine ...
The lifted hold applies to Novavax’s flu ... combo vaccine. A trial participant who’d received the shot in Jan. 2023 later developed motor neuropathy, or muscle weakness, leading the FDA ...
Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu vaccine that had been put on hold.
The FDA lifted its clinical hold on Novavax's COVID-flu vaccine trial. The hold was due to unrelated safety concerns, allowing trial resumption. Novavax aims for growth with its combination shot ...
Novavax is already poised to benefit from a separate combined Covid-flu vaccine ... combined shot. Meanwhile, Moderna said last week that it plans to file for FDA approval of its own combo vaccine ...
(Reuters) -The U.S ... hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines after a safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results